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Oxidative stress and inflammation contribute to the
pathogenesis of cisplatin-induced nephrotoxicity. We found
that genistein, a tyrosine kinase inhibitor with broad
specificities, and which also has estrogen-like activity, had
protective effects on cisplatin-induced renal injury in mice.
Genistein significantly decreased reactive oxygen species
production, the expression of intercellular adhesion
molecule-1 and monocyte chemoattractant protein-1
proteins, as well as the translocation of the p65 subunit of
nuclear factor-jB into the nucleus and the infiltration of
macrophages, all of which were increased in the kidney by
cisplatin treatment. Genistein also decreased cisplatin-
induced apoptosis by regulating p53 induction in kidney.
Genistein significantly reduced reactive oxygen species
production in cisplatin-treated normal human kidney HK-2
cells. These studies show that genistein or similar compounds
might be useful in prevention of cisplatin-induced renal
injury.
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cis-Diamminedichloroplatinum (cisplatin) is one of the most
effective chemotherapeutic agents and is used to treat various
types of solid tumors, including testicular, ovarian, head,
neck and uterine cervical carcinomas.1 Nephrotoxicity is a
frequent adverse effect of cisplatin-based chemotherapy and
is the major limitation of its use. About 25–35% of patients
experience a significant decline in renal function after a single
dose of cisplatin.2 Cisplatin-induced nephrotoxicity occurs
through direct tubular toxicity, inflammation, vascular
factors and oxidative stress.3,4 Oxidative stress is caused by
various free oxygen radicals in kidney, including the super-
oxide anion, the hydrogen peroxide and the hydroxyl radical.
Reactive oxygen species (ROS) also important in enhancing
inflammation through the activation of nuclear factor-kB
(NF-kB). Oxidative stress and inflammation have been
suggested to be the major mechanisms in the pathogenesis
of cisplatin-induced nephrotoxicity.5,6
Genistein, a polyphenolic nonsteroidal isoflavonoid de-
rived from soybean, has estrogen-like activity. It binds to
estrogen receptors and inhibits tyrosine kinase activity7 and
protects against breast and prostate cancer.8,9 Genistein also
has anti-inflammatory properties through its downregulation
of cytokine-induced signal transduction events in the cells of
the immune system.10,11 Pretreatment of RAW264.7 macro-
phages with genistein inhibits the release of both tumor
necrosis factor-a and interleukin-6 stimulated by lipo-
polysaccharide (LPS). Genistein also suppresses endotoxin-
induced inflammatory reactions in the liver and intestines in
vivo.12 However, the protective role of genistein against
cisplatin-induced renal injury has not been investigated.
In this study, we investigated the protective effect of
genistein against cisplatin-induced renal injury in mice and
examined the mechanism of this protection in mice and
normal adult human kidney (HK-2) cells. Our results showed
that genistein reduces functional and histological renal
damage caused by cisplatin. Genistein suppressed the
generation of ROS and NF-kB activation, leading to a
decrease in the expression of cisplatin-induced intracellular
adhesion molecule-1 (ICAM-1) and monocyte chemo-
attractant protein-1 (MCP-1). Genistein also decreased
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cisplatin-induced apoptosis through the regulation of p53
induction in kidney. These results indicate that genistein
protects against cisplatin-induced renal injury.
RESULTS
Genistein reduces renal dysfunction in mice with
cisplatin-induced renal injury
To investigate the effects of genistein on cisplatin-induced
renal dysfunction, we treated mice with cisplatin, genistein,
or both, and measured the levels of blood urea nitrogen
(BUN) and creatinine 72 h later. Control buffer injections
were used as a control. Cisplatin administration elevated
BUN and creatinine levels to 137.2±22.3 and 1.32±0.19 mg/
100 ml, respectively, from the levels in control (23±5 and
0.32±0.06 mg/100 ml, respectively; Figure 1). The addition
of genistein treatment to the cisplatin significantly decreased
BUN levels (to 41.1±9.7 mg/100 ml) and serum creatinine
levels (to 0.48±0.12 mg/100 ml) from the levels with
cisplatin alone. BUN and creatinine levels after treatment
with genistein alone (BUN, 24±2 mg/100 ml; creatinine
0.4±0.09 mg/100 ml) did not differ from the levels in the
control group.
Genistein ameliorates cisplatin-induced renal tubular
damage
To investigate the effect of genistein on cisplatin-induced
renal tubular damage, we stained kidney sections with
periodic acid Schiff (PAS). Atrophy and degeneration of
epithelial cells, accumulation of PAS-positive materials, and
hyaline materials in the tubular lumen were evident in the
cisplatin-treated group. However, after treatment with
genistein plus cisplatin, the damage was limited to mild
swelling of the tubular epithelial cells, and less histological
damage was visible with the PAS stain (Figure 2a).
Pretreatment with genistein significantly reduced the tubular
necrosis score compared to the score in sections from mice
treated with cisplatin alone (Figure 2b).
Genistein reduces ICAM-1 and MCP-1 expression in
cisplatin-induced renal injury
Cisplatin injection results in the upregulation of a number of
proinflammatory cytokines and chemokines in the kidney.4
Therefore, we used immunostaining to evaluate whether
genistein could reduce the elevation of ICAM-1 and MCP-1
expression caused by cisplatin-induced renal injury. Renal
sections from cisplatin-treated mice displayed markedly
increased ICAM-1 staining in the brush border of the
proximal tubules and the interstitium compared to those
from vehicle-treated control mice (Figure 3). Using confocal
microscopy, we also found that ICAM-1 was expressed on the
endothelial cell in the interstium after cisplatin treatment
(Supplementary Figure 1). Genistein significantly reduced
ICAM-1 staining in the tubular epithelial cells and inter-
stitium compared to the group treated with cisplatin alone
(Figure 3a). Consistent with the results obtained with
immunostaining, a western blot analysis revealed that the
protein levels of ICAM-1 were lower in the renal tissues of
mice treated with genistein and cisplatin than in those of
mice treated with cisplatin alone (Figure 3b).
As with ICAM-1 expression, MCP-1 staining was
markedly higher in the proximal tubules and interstitium
in renal sections from mice treated with cisplatin than in
renal sections from vehicle-treated mice. Genistein markedly
reduced MCP-1 staining from the level seen in cisplatin-
treated mice (Figure 4).
Genistein inhibits the infiltration of macrophages in
cisplatin-induced renal injury
The number of F4/80-postitive macrophages infiltrating the
renal interstitium was markedly increased in the cisplatin
group (32±7 in 10 fields at  400 magnification) compared
to the control (6±2 in 10 fields at  400 magnification;
Figure 5), and this increase was significantly reduced when
the animals were treated with genistein in addition to
cisplatin (15±6 in 10 fields at  400 magnification).
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Figure 1 | Effects of genistein on BUN and serum creatinine in cisplatin-induced acute renal injury. Acute renal injury was induced by
intraperitoneal injection of cisplatin (Cis; 20 mg/kg). Mice were administered genistein (Geni; 10 mg/kg orally) once a day for 3 days after
cisplatin injection. Blood samples were collected 72 h after cisplatin administration, then (a) BUN and (b) serum creatinine were measured.
Control mice (Cont) were injected with control buffer. Values are means±s.e.m. (n¼ 10 mice per group). *Po0.05 vs Cont; wPo0.05 vs Cis.
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Figure 2 | Effect of genistein on renal histology in cisplatin-induced acute renal injury. Sections of kidney were stained with PAS 72 h
after cisplatin injection. (a) Control buffer treatment alone (Cont); genistein treatment alone (Geni); cisplatin treatment alone (Cis); treatment
with cisplatin and genistein (CisþGeni) (bar¼ 50 mm). (b) Tubular necrosis was scored in harvested renal tissues (see the ‘Materials and
Methods’ for the scoring method). The cisplatin-treated kidneys (Cis) showed marked injury, with cast formation, sloughing of tubular
epithelial cells, loss of brush border, and dilatation of the tubules. These changes were less pronounced in mice treated with cisplatin and
genistein (CisþGeni). Genistein treatment alone (Geni) had no effect on renal histology (n¼ 10 for each experimental group). Data are the
means±s.e.m. *Po0.05 vs Cont; wPo0.05 vs Cis.
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Figure 3 | Effect of genistein on ICAM-1 expression in cisplatin-induced acute renal injury. (a) Immunostaining for intercellular adhesion
molecule-1 (ICAM-1) in renal tissue. Control buffer treatment alone (Cont); genistein treatment alone (Geni); cisplatin treatment alone (Cis);
treatment with cisplatin and genistein (CisþGeni). The sections are counterstained with hematoxylin. Note that the expression of ICAM-1 was
increased by cisplatin in renal proximal tubular epithelial cells and the interstitium. Administration of genistein significantly reduced the
expression of ICAM-1 after cisplatin injection (bar¼ 50mm). (b, c) Western blots and corresponding densitometric analysis of ICAM-1 expression
in renal tissue. Data in the densitometric analysis are the means±s.e.m. of four independent experiments. *Po0.05 vs Cont; wPo0.05 vs Cis.
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Genistein inhibits cisplatin-induced NF-jB activation in renal
injury
We previously reported that NF-kB p65 staining markedly
increases in the renal tubular cells of cisplatin-treated mice.13
We therefore carried out immunohistochemistry to evaluate
the activity and translocation of p65 in kidney sections from
cisplatin- and genistein-treated mice. In cisplatin-treated mice,
nuclear staining of p65 markedly increased in renal
tubular cells. However, in mice treated with genistein as well
as cisplatin, nuclear staining in renal tubular cells was
significantly lower than in the cisplatin-treated group (Figure
6a and b).
To further investigate the mechanisms of the effect of
genistein on nephrotoxicity, we treated cultured HK-2 cells
with cisplatin, genistein, or both. Consistent with the
immunohistochemical data, a western blot analysis showed
that levels of NF-kB p65 protein in nuclear extracts of renal
tubular HK-2 cells were higher after cisplatin treatment than
in the control. Genistein treatment reduced the increased NF-
kB p65 levels in the nuclear protein extracts from HK-2 cells
after cisplatin treatment. Electrophoretic mobility shift assay
revealed that NF-kB–DNA binding increased in nuclear
extracts from HK-2 cells treated with cisplatin, and this
increase was significantly reduced by the administration of
genistein (Figure 6d).
Genistein reduces ROS production and restores GSH
concentrations in cisplatin-treated renal tubular
epithelial cells
Oxidative stress can be caused by various free oxygen radicals
and has been implicated in the pathogenesis of cisplatin-
induced nephrotoxicity. Therefore, we evaluated the role of
genistein in countering cisplatin-induced oxidative stress.
ROS generation in HK-2 cells was significantly higher after
cisplatin treatment than in control. This increase in ROS
generation was significantly reduced by treatment with
genistein (Figure 7a).
Glutathion (GSH) is an important endogenous antiox-
idant that protects nearly all cells and tissues from oxygen
radical damage. We investigated whether genistein restores
GSH levels in cisplatin-treated HK-2 cells. GSH concentra-
tions were greater in HK-2 cells treated with both genistein
and cisplatin than in those treated with cisplatin alone
(Figure 7b).
Genistein reduces cisplatin-induced apoptosis with the
downregulation of p53 induction in renal injury
Because it has been reported that p53 is involved in cisplatin-
induced apoptosis,14,15 we investigated whether genistein
reduces cisplatin-induced apoptosis in kidney through the
regulation of p53 induction. Cisplatin increased the number
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Figure 4 | Effect of genistein on MCP-1 expression in cisplatin-induced acute renal injury. (a) Immunostaining for monocyte
chemoattractant protein-1 (MCP-1) in renal tissue. Control buffer treatment alone (Cont); genistein treatment alone (Geni); cisplatin
treatment alone (Cis); treatment with cisplatin and genistein (CisþGeni). Note that the expression of MCP-1 is highest in the cisplatin-
treated kidney section (arrows) and genistein decreased the expression of MCP-1 in the cytoplasm of the renal proximal tubular epithelial
cells in cisplatin-induced renal injury (open arrows) (bar¼ 50mm). (b) Semiquantitative score of MCP-1 expression in renal tissue. The
administration of genistein significantly reduced the expression of MCP-1 after cisplatin injection. The extent of MCP-1 immunostaining was
assessed semiquantitatively, as described in the ‘Materials and Methods’ (n¼ 5 for each experimental group). Data are the means±s.e.m.
*Po0.05 vs Cont; wPo0.05 vs Cis.
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of apoptotic cells and accumulated p53-positive cells in same
tissue, and genistein significantly decreased the cisplatin-
induced apoptosis and p53 accumulation (Figure 8). An
immunoblot analysis showed an increase of p53 induction in
kidney after cisplatin treatment, and genistein decreased the
cisplatin-induced the p53 induction in kidney (Figure 9).
DISCUSSION
In this study, we have demonstrated that (1) the adminis-
tration of genistein significantly reduces cisplatin-induced
renal injury, as assessed with functional and histologic
measures; (2) genistein ameliorates the cisplatin-induced
upregulation of ICAM-1 and MCP-1 expression, resulting in
decreased infiltration of macrophages into the kidney; (3) the
administration of genistein significantly reduces cisplatin-
induced generation of ROS and NF-kB activation in HK-2
cells and (4) genistein reduces cisplatin-induced apoptosis in
kidney through downregulation of p53 induction.
Genistein is the predominant isoflavone phytoestrogen
found in soy. Soy-based diets are high in phytochemicals,
and isoflavone phytoestrogens are normal constituents of
human urine.16,17 Genistein has been shown to compete
with 17 b-estradiol for estrogen receptor binding because of
its structural similarity, resulting in antagonistic activity and
it inhibits cell growth in breast and prostate cancers in vivo
and in vitro.8,9 Furthermore, genistein has been found to
regulate genes that are critical for the control of cell
proliferation, the cell cycle, apoptosis, and transcriptional
regulation.18
ROS, particularly the superoxide radical, is important in
cisplatin-induced nephrotoxicity. The excessive ROS accu-
mulation induced by cisplatin causes an imbalance in the
antioxidant status and leads to lipid peroxidation and GSH
depletion.5 Free radical scavengers and antioxidants can
ameliorate cisplatin-induced nephrotoxicity. An increase in
the intracellular GSH concentration reduces the renal damage
caused by the toxic effects of free radicals that are created
during reperfusion after ischemic injury.19 Thus, the tissue
level of ROS in kidney is an important factor in cisplatin-
induced renal injury. We previously reported that the
antioxidant L-2-oxothiazolidine-4-carboxylic acid reduced
nephrotoxicity through reduction of the ROS concentration
in cisplatin-treated kidney.13
Genistein has an antioxidant effect that may counteract
the effect of ROS generated by cisplatin.20 Genistein increases
GSH levels previously decreased by LPS treatment in
macrophages.21 Dietary isoflavones have a similar effect in
vivo: oral intake of isoflavones increased the levels of the
antioxidant in the livers of mice treated with LPS and oral
administration of genistein ameliorates LPS-induced decrease
of GSH level.22,23 Thus, the administration of genistein
effectively replenishes GSH levels. In this study, cisplatin
markedly increased ROS production and reduced GSH levels
in HK-2 cells and kidney, but the concomitant administra-
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Figure 5 | Effect of genistein on the infiltration of macrophages in cisplatin-induced acute renal injury. (a) Immunostaining for
F4/80-positive macrophages in renal tissue. Control buffer treatment alone (Cont); genistein treatment alone (Geni); cisplatin treatment
alone (Cis); treatment with cisplatin and genistein (CisþGeni). Note that the number of F4/80-positive cells (arrows) is highest in the
cisplatin-treated kidney section and genistein decreased the number of F4/80-positive cells in cisplatin-induced renal injury (open arrows)
(bar¼ 50mm). (b) Number of F4/80-positive cells in 10  400 fields. Data are the means±s.e.m. (n¼ 5 for each experimental group).
*Po0.05 vs Cont; wPo0.05 vs Cis.
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Figure 6 | Effect of genistein on NF-jB activation in cisplatin-induced acute renal injury and in HK-2 cells. (a) Immunohistochemical
detection of the translocation of NF-kB p65 in kidney sections. Note that the number of renal tubular cells showing nuclear staining with
NF-kB p65 was significantly increased in the Cis group (arrows) compared to control and the number of cells showing nuclear staining in the
CisþGeni group was significantly lower than that of the Cis group (open arrows)( bar¼ 50 mm). (b) Semiquantitative score of NF-kB p65
expression in renal tissue. The number of NF-kB-activated cells in 10  400 fields was assessed as described in the ‘Materials and Methods’
(n¼ 5 for each experimental group). Data are the means±s.e.m. *Po0.05 vs Cont; wPo0.05 vs Cis. (c) NF-kB p65 expression in nuclear
protein extracts from HK-2 cells. (d) Representative electrophoretic mobility shift assay of nuclear extracts from HK-2 cells. NF-kB expression
was measured in control HK-2 cells with PBS treatment (Cont); with genistein treatment alone (Geni); cisplatin treatment alone (Cis); and
treatment with cisplatin and genistein (CisþGeni). NS, nonspecific; FP, free probe. Note that NF-kB–DNA binding activities increased in
nuclear extracts from HK-2 cells treated with cisplatin, and this increase was significantly reduced by genistein. Data are the means±s.e.m.
of four independent experiments. *Po0.05 vs Cont; wPo0.05 vs Cis.
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Figure 7 | Effects of genistein on production of ROS and restoration of GSH concentrations in cisplatin-treated HK-2 cells. (a)
Reactive oxygen species (ROS) levels were measured in HK-2 cells using dichlorofluorescein diacetate (DCF-DA). The relative level of ROS in
HK-2 cells treated with PBS was arbitrarily given the value of 100. (b) Glutathion (GSH) levels were measured in HK-2 cells using the
Glutathione Assay Kit II. PBS treatment alone (Cont); genistein treatment alone (Geni); cisplatin treatment alone (Cis); treatment with
cisplatin and genistein (CisþGeni). Data are expressed as percentages of the PBS-treated control group. Data are the means±s.e.m. of four
independent experiments. *Po0.05 vs Cont; wPo0.05 vs Cis.
Kidney International (2008) 74, 1538–1547 1543
MJ Sung et al.: Genistein reduces cisplatin nephrotoxicity o r i g i n a l a r t i c l e
tion of genistein reduced the production of ROS and restored
normal GSH concentrations, suggesting that genistein
restores balance to the antioxidant system in cisplatin-treated
kidney.
The ROS activates the transcription factor NF-kB during
cisplatin-induced renal injury.13 Cisplatin also activates
proinflammatory cytokines and chemokines, whose accumu-
lation is likely to trigger the expression of adhesion
molecules.4,13,24 It has been suggested that genistein has an
anti-inflammatory effect11 as well as an antioxidant effect. The
in vivo and in vitro administration of genistein suppresses LPS-
induced proinflammatory cytokines such as tumor necrosis
factor-a and interleukin-1b in the liver, and intraperitoneally
injected genistein protects rats from LPS-induced organ
failure.25 Genistein prevents the NF-kB activation and acute
lung injury induced by LPS.26 In our experimental data,
cisplatin treatment significantly increased the expression of
ICAM-1, MCP-1, and the number of infiltrating macrophages
in the kidney and the NF-kB binding activities of renal tubular
epithelial cells. ROS may act as second messengers in NF-kB
activation, and antioxidants suppress NF-kB activation.13 Our
results demonstrate that genistein indirectly suppresses the
NF-kB activation induced by ROS and subsequently inhibits
the transcription of a variety of inflammatory genes during
cisplatin-induced renal injury in mice.
The activation of p53 has been associated with cisplatin-
induced nephrotoxicity.14 In this experiment, we also
demonstrated that genistein decreased the cisplatin-induced
increase in p53 in renal tissue. We therefore suggest that
genistein decreases cisplatin-induced apoptosis through the
regulation of p53 induction in kidney.
It has been reported that genistein has anticancer activity
in prostate and breast cancer.8 They suggested that inactiva-
tion of NF-kB by genistein contribute to increased growth
inhibition and apoptosis induced by cisplatin in prostate,
breast cancer without causing systemic toxicity. In our data,
genistein inhibits NF-kB activation and prevent in cisplatin-
induced renal injury. Therefore, genistein can be a good
candidate to improve cisplatin-induced anticancer activity
and to prevent in cisplatin-induced kidney injury in cancer
patients treated with cisplatin.
In conclusion, our study provides evidence that genistein,
which reduces ROS levels and the subsequent reduction of
NF-kB, has significant potential as a therapeutic intervention
for cisplatin-induced renal injury.
MATERIALS AND METHODS
Animals and drug treatments
Male C57BL/6 mice (Charles River Korea, Seoul, Korea) were given a
standard laboratory diet and water ad libitum and were maintained
under a protocol approved by the Institutional Animal Care and Use
Committee of the Korea Food Research Institute. At the start of the
experiments, the mice were 8–10 weeks of age, weighing 25–30 g. The
mice were divided into four groups: control (n¼ 10), genistein
(10 mg/kg; Sigma Chemical Co., St Louis, MO; n¼ 10), cisplatin
(20 mg/kg; Sigma Chemical Co.; n¼ 10), and cisplatin plus genistein
(n¼ 10). The dose of cisplatin and the time of treatment were
chosen according to a previously used method,13 and renal injury, as
determined by BUN and serum creatinine levels and histological
Cont Cis Cis+Geni
p53
TUNEL
Merge
N
um
be
r o
f  
TU
NE
L-
a
n
d 
p5
3-
po
sit
ive
 c
el
ls
Cont Geni Cis Cis+Geni
†
0
2
4
6
8
10
*
Figure 8 | Effects of genistein on cisplatin-induced apoptosis and p53 induction in kidney. (a) C57BL/6 mice were injected with control
buffer (Cont), cisplatin (Cis), or cisplatin and genistein (CisþGeni). Renal tissues were collected 3 days after injection of cisplatin or control
buffer to measure apoptosis with the TUNEL assay and accumulated p53 with an immunohistochemical analysis. Note that genistein
decreased the number of cisplatin-induced TUNEL- and accumulated p53-positive cells in kidney sections. Arrows indicate TUNEL- and
accumulated p53-positive cells (bar¼ 50 mm). (b) Number of TUNEL- and p53-positive cells in 10  400 fields. Data are the means±s.e.m.
(n¼ 7 for each experimental group). *Po0.05 vs Cont; wPo0.05 vs Cis.
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findings, was clearly seen with a dose of 20 mg/kg cisplatin
(intraperitoneal) at 72 h after the cisplatin treatment. The dose of
genistein (10 mg/kg) was chosen according to a method reported
previously.27 Genistein was administered by oral gavage once a day
for 3 days until the mice were killed 72 h after the cisplatin injection,
at which time the mice were anesthetized with ketamine (100 mg/kg)
and xylazine (10 mg/kg) and killed by cervical dislocation.
Renal function monitoring
Blood was collected from intracardiac puncture immediately after the
mice were killed. Urea nitrogen and creatinine levels in the serum were
measured using enzymatic methods (SRL, Tokyo, Japan).
Histological examinations
The mouse kidneys were sectioned in blocks and fixed in 4%
paraformaldehyde, then dehydrated in graded concentrations of
alcohols and embedded in paraffin. The kidney block was cut into
10-mm sections and stained with PAS reagents. The tubular damage
in the PAS-stained sections was graded according to the percentage
of cortical tubules with epithelial necrosis: 0¼ normal; 1p10%;
2¼ 10–25%; 3¼ 26–75%; 4X75%. Tubular necrosis was defined as
the loss of the proximal tubular brush border, blebbing of the apical
membranes, tubular epithelial cell detachment from the basement
membrane, or intraluminal aggregation of cells and proteins. The
morphometric examinations were performed in a blinded manner
by two independent investigators. In brief, investigators were
unaware of the contents of the various experimental groups until
after clearance studies and histopathologic grading were completed.
The investigator grading the histopathologic slides was also blinded
to the treatment groups.
Immunohistochemical analysis of ICAM-1, MCP-1, F4/80, and
NF-jB p65
Immunohistochemical staining for ICAM-1, MCP-1, F4/80, and
NF-kB p65 was performed as described previously.13 Isolated kidney
tissues were fixed by immersion in 4% paraformaldehyde and
embedded in paraffin. Tissue sections were deparaffinized with
xylene and rehydrated with ethanol. Endogenous peroxidase was
blocked with 3% hydrogen peroxide for 20 min, and the samples
were then rinsed with phosphate buffered saline (PBS). To obtain an
adequate signal, the slides were treated with pepsin at 42 1C for
5 min. After treatment with blocking buffer, the slides were
incubated overnight at 4 1C with a hamster anti-mouse ICAM-1
antibody (dilution 1:100; BD Pharmingen, San Diego, CA, USA), a
rabbit anti-mouse MCP-1 antibody (dilution 1:100; Fitzgerald,
Concord, MA, USA), a rat anti-mouse F4/80 antibody (dilution
1:50; Serotec, Oxford, UK), or a rabbit polyclonal antibody directed
against NF-kB p65 (dilution 1:100; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). The primary antibody was localized using the
Vectastain ABC Elite Peroxidase Detection System (Vector Labora-
tories, Burlingame, CA, USA), followed by reaction with diamino-
benzidine as the chromogen and counterstaining with hematoxylin
(Sigma Chemical Co.). All the slides were evaluated by two observers
who were unaware of the origins of the slides. The numbers of
F4/80-positive cells or NF-kB-activated cells in each section were
calculated by counting the number of positively stained cells in 10
fields per slide at a magnification of  400. The extent of MCP-1
immunostaining in the cortical tubulointerstitium was graded on a
scale from 0 to 4 under a micrometric ocular grid in 10 fields per
slide at a magnification of  400: 0¼ normal; 1p10%; 2¼ 10–25%;
3¼ 26–75%; 4X75%.
Cell culture and application of cisplatin and genistein to
HK-2 cells
An immortalized proximal tubule epithelial cell line from HK-2 was
purchased from the American Type Culture Collection (Manassas,
VA, USA) and cultured. Briefly, cells were passaged every 3–4 days in
100-mm dishes (Falcon, Bedford, MA, USA) using Dulbecco’s
modified Eagle’s medium-F12 (Sigma Chemical Co.) supplemented
with 10% fetal bovine serum (Life Technologies Inc., Gaithersburg,
MD, USA), insulin-transferrin-sodium selenite media supplement
(Sigma Chemical Co.), 100 U/ml penicillin, and 100mg/ml strepto-
mycin (Sigma Chemical Co.). These cells were incubated in a
humidified atmosphere of 5% CO2, 95% air at 37 1C for 24 h and
subcultured at 70–80% confluence. For experimental use, HK-2 cells
were plated onto 60-mm dishes in medium containing 10% fetal
bovine serum for 24 h and cells were then switched to Dulbecco’s
modified Eagle’s medium-F12 with 2% fetal bovine serum for 16 h.
These cells were treated with cisplatin (1mg/ml; Sigma Chemical
Co.) in the presence or absence of genistein (25 mg/l; Sigma
Chemical Co.) for 6 h. Control cells received buffer only instead of
genistein and/or cisplatin. The cells were harvested at the end of the
treatment for further analysis.
Western blot analysis
Western blot analysis was performed as described previously.13
Kidney tissues were homogenized in PBS with protease inhibitor
cocktail (Calbiochem, San Diego, CA, USA) and the protein
concentration was quantitated. The samples (40 mg of protein per
lane) were mixed with sample buffer, boiled for 10 min, separated by
SDS–polyacrylamide (10%) gel electrophoresis under denaturing
conditions, and electroblotted onto nitrocellulose membranes. The
nitrocellulose membranes were blocked with 5% nonfat dry milk in
TRIS buffered saline with Tween 20 buffer (25 mmol/l Tris (pH 7.5),
150 mmol/l NaCl, 0.1% Tween 20) for 1 h and incubated overnight
at 4 1C with an anti-ICAM-1 monoclonal antibody (dilution 1:2000;
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Figure 9 | Suppression of p53 induction by genistein during
cisplatin treatment in kidney. C57BL/6 mice were injected with
control buffer (Cont), cisplatin (Cis), or cisplatin and genistein
(CisþGeni). (a) Immunoblot analysis of p53 (Ser 15) in kidney
treated with cisplatin and/or genistein. (b) Densitometric analysis
of p53 in renal tissue. Data are the means±s.e.m. of three
independent experiments. *Po0.05 vs Cont; wPo0.05 vs Cis.
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Santa Cruz Biotechnology) or an anti-p53 antibody (dilution
1:2000; Santa Cruz Biotechnology). The blots were washed with
PBS and incubated with horseradish peroxidase-conjugated anti-
rabbit IgG. The signals were visualized with a chemiluminescent
detection kit according to the manufacturer’s protocol (Amersham
Pharmacia Biotech, London, UK). The membranes were reprobed
with an anti-actin antibody to verify the equal loading of protein in
each lane. All signals were visualized and analyzed by densitometric
scanning (LAS-3000; Fuji Film, Tokyo, Japan).
Electrophoretic mobility shift assay
An electrophoretic mobility shift assay was performed as described
previously.28 Electrophoretic mobility shift assay for NF-kB
protein was performed with the biotin-labeled NF-kB binding-site
oligomer 50-AGTTGAGGGGACTTTCCCAGGC-30. The signals were
detected by chemiluminescent imaging according to the manufac-
turer’s protocol (EMSA Gel-Shift Kit; Panomics, Redwood City,
CA, USA).
Measurement of intracellular ROS
To measure intracellular ROS, HK-2 cells were incubated for 10 min
at room temperature with PBS containing 20,70-dichlorofluorescein
diacetate (Molecular Probes, Eugene, OR). The cells were rinsed
twice with PBS. Dichlorofluorescein diacetate fluorescence was
analyzed using a SpectraMax M2e spectrophotometer (Molecular
Devices, Bath, UK). Dichlorofluorescein diacetate was excited at
488 nm and the fluorescein signal was analyzed at 525 nm.
Measurement of glutathione
GSH levels were measured in HK-2 cells using the Glutathione Assay
Kit II (Calbiochem, Darmstadt, Germany), according to the
protocol provided by the manufacturer. Briefly, HK-2 cells were
homogenized in 1 ml of ice-cold lysis buffer and centrifuged at
10,000 g for 15 min at 4 1C. The supernatant was deproteinized with
5% metaphosphoric acid (Sigma Chemical Co.) and 4 mol/l
triethanolamine (Sigma Chemical Co.). The samples were then
mixed with the assay cocktail reagents. After incubation at 25 1C for
25 min, absorbance was measured at 405 nm. GSH levels were
calculated using a standard curve generated with the standards
provided by the manufacturer.
Immunofluorescence double staining
The immunofluorescence staining of kidney tissue was conducted as
described.24 Briefly, freshly frozen renal tissues were fixed with 4%
paraformaldehyde, permeabilized in 1% Triton X-100 and then
incubated with a blocking buffer. Subsequently, the samples were
incubated with the anti-p53 antibody (dilution 1:10; Santa Cruz
Biotechnology). The slides were exposed to Cy3-labeled secondary
antibody (Chemicon, Temecula, CA, USA). After tissues were
incubated with the TUNEL (Roche Applied Science, Indianapolis,
IN, USA) reaction mixture containing terminal deoxynucleotidyl
transferase and nucleotides including fluorescein isothiocyanate-
labeled dUTP. The staining was examined by fluorescence and
confocal microscopy.
Statistical analysis
Data are expressed as means±s.e.m. Multiple comparisons were
examined for significant differences using analysis of variance,
followed by individual comparisons with the Tukey’s post hoc test.
Statistical significance was set at Po0.05.
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SUPPLEMENTARY MATERIAL
Figure S1. Coexpression of ICAM-1 and PECAM-1 on renal interstitial
endothelial cells.
Figure S2. The effect of genistein on cell cytotoxicity in cisplatin-
treated HK-2 cells.
Figure S3. Effect of genistein on apoptosis in cisplatin-induced HK-2
cells.
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